Sudeep Pharma Ltd

With a decisive surge to Rs 815.85 on 1 Jun 2026, Sudeep Pharma Ltd has reached a new 52-week and all-time high, propelled by a confluence of strong technical signals and sustained price momentum.

The Sensex edged up by a modest 0.15% on 1 Jun 2026, while Sudeep Pharma Ltd surged 7.84%, marking a standout session in the Pharmaceuticals & Biotechnology sector with a 7.65 percentage-point outperformance. This sharp intraday gain rewrites the short-term narrative for the small-cap stock, which also hit a new 52-week and all-time high of Rs 815.85 during the day.

Sudeep Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance, supported by robust price appreciation and encouraging technical indicator signals. The stock’s recent 10.00% day gain to ₹741.70, nearing its 52-week high of ₹795.80, highlights renewed investor interest in this small-cap pharmaceutical player amid broader market headwinds.

At Rs 742.15, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sudeep Pharma Ltd locked at its upper circuit of 10% on 29 May 2026, with buyers queuing and no sellers willing to part with shares.

The Sensex advanced 0.24% on 29 May 2026, yet Sudeep Pharma Ltd outpaced the broader market with a robust 7.64% gain, reaching an intraday high of Rs 725. This 5.72 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Sudeep Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a robust 3.77% gain on 26 May 2026, the stock’s technical indicators suggest a nuanced outlook, with mixed signals from MACD, RSI, and moving averages. This article analyses the recent price action, technical parameters, and relative performance against the Sensex to provide a comprehensive view for investors.

The Sensex advanced 1.21% on 25 May 2026, yet Sudeep Pharma Ltd outpaced the broader market with a 7.62% gain, reaching an intraday high of Rs 714.95. This 5.79-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.

Sudeep Pharma Ltd has been assigned a Hold rating with a Mojo Score of 64.0, reflecting a notable upgrade from its previous ungraded status. This change, effective from 22 May 2026, is driven by significant improvements across four key parameters: financial trend, quality, valuation, and technicals. The company’s recent quarterly performance, alongside evolving market dynamics, has prompted this reassessment, positioning Sudeep Pharma as a cautiously optimistic pick within the Pharmaceuticals & Biotechnology sector.

Sudeep Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. Recent technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, suggest a cautiously optimistic outlook for the stock, supported by positive price action and relative strength compared to the broader market.

Sudeep Pharma Ltd has recently seen its quality grade upgraded from 'Does Not Qualify' to 'Good' by MarketsMOJO, reflecting a marked improvement in its business fundamentals. This upgrade, announced on 22 May 2026, highlights enhanced operational efficiency, robust return ratios, and prudent debt management, positioning the small-cap pharmaceutical company favourably within its sector.

Sudeep Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was assigned on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 23 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sudeep Pharma Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹7,409.00 crores, reported consolidated net profit of ₹48.88 crores for Q4 FY26, marking a sequential growth of 2.99% and year-on-year expansion of 10.61%. The stock currently trades at ₹671.65, up 0.54% in the latest trading session, though it remains 15.60% below its 52-week high of ₹795.80.